Press Releases Spago Nanomedical AB

Equities

SPAG

SE0004899474

Market Closed - Nasdaq Stockholm Other stock markets 10:42:26 2024-04-26 am EDT			5-day change	1st Jan Change
0.36 ^SEK	+0.56%		+8.76%	+10.09%

Apr. 24	Spago Nanomedical AB Reports Favorable Data in Breast Cancer Model with Tumorad	CI
Apr. 16	Spago Nanomedical AB Announces Appointment of Birgitta Rembratt Svensson as Head of CMC & Supply, Effective June 1, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Spago Nanomedical reports favorable data in breast cancer model with Tumorad	Apr. 24	AQ
Spago Nanomedical strengthens management with Head of CMC and Supply	Apr. 17	AQ
Spago Nanomedical strengthens management with Head of CMC & Supply	Apr. 16	AQ
BioStock: Spago Nanomedical's CEO: "huge commercial opportunities are unfolding"	Mar. 27	AQ
BioStock: 2023 springboard for Spago's radionuclide cancer therapy	Feb. 09	AQ
Spago Nanomedical Q4 Update	Feb. 08	AQ
Spago Nanomedical year-end report January-December, 2023	Feb. 07	AQ
The rights issue and the directed share issue to certain guarantors in Spago Nanomedical fully registered	Jan. 25	AQ
Spago Nanomedical presents at Redeye's Fight Cancer event on January 24	Jan. 19	AQ
Spago Nanomedical presents at Redeye’s Fight Cancer event on January 24	Jan. 18	AQ
BioStock: Spago's phase I/IIa cancer trial progressing steadily	Jan. 15	AQ
Spago Nanomedical proceeds to the next dose level in the phase I/IIa study Tumorad-01	Jan. 10	AQ
Spago Nanomedical - Update after funding and initiation of Tumorad	Jan. 03	AQ
BioStock: Positive data in Spago's phase IIa endometriosis trial	Dec. 20	AQ
Spago Nanomedical reports positive top line data from clinical phase IIa study SPAGOPIX-02 in patients with endometriosis	Dec. 15	AQ
BioStock: First patient dosed in Spago's phase I/IIa trial	Dec. 14	AQ
Spago Nanomedical carries out a directed issue of shares to guarantors following the completed rights issue	Dec. 13	AQ
Rights issue in Spago Nanomedical partially registered	Dec. 12	AQ
First patient dosed in Spago Nanomedical's clinical phase I/IIa study within the Tumorad program	Dec. 08	AQ
First patient dosed in Spago Nanomedical's clinical phase I/IIa study within the Tumorad® program	Dec. 07	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Spago Nanomedical AB

Equities

SPAG

SE0004899474

Press Releases

Filters